ECSP21001770A - Degradadores selectivos del receptor de estrógeno - Google Patents

Degradadores selectivos del receptor de estrógeno

Info

Publication number
ECSP21001770A
ECSP21001770A ECSENADI20211770A ECDI202101770A ECSP21001770A EC SP21001770 A ECSP21001770 A EC SP21001770A EC SENADI20211770 A ECSENADI20211770 A EC SENADI20211770A EC DI202101770 A ECDI202101770 A EC DI202101770A EC SP21001770 A ECSP21001770 A EC SP21001770A
Authority
EC
Ecuador
Prior art keywords
selective
receptor degraders
strogen
strogen receptor
degraders
Prior art date
Application number
ECSENADI20211770A
Other languages
English (en)
Inventor
Almudena Rubio
Jolie Anne Bastian
Jeffrey Daniel Cohen
Daniel Jon Sall
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21001770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21001770A publication Critical patent/ECSP21001770A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

FAVOR VER RESUMEN ADJUNTO
ECSENADI20211770A 2018-07-12 2021-01-12 Degradadores selectivos del receptor de estrógeno ECSP21001770A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12

Publications (1)

Publication Number Publication Date
ECSP21001770A true ECSP21001770A (es) 2021-02-26

Family

ID=67470734

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20211770A ECSP21001770A (es) 2018-07-12 2021-01-12 Degradadores selectivos del receptor de estrógeno

Country Status (37)

Country Link
US (4) US10654866B2 (es)
EP (2) EP4155310A1 (es)
JP (6) JP6995241B2 (es)
KR (3) KR102783756B1 (es)
CN (2) CN112638916B (es)
AR (3) AR115694A1 (es)
AU (2) AU2019299947B2 (es)
BR (1) BR122023025061A2 (es)
CA (1) CA3105501C (es)
CL (1) CL2021000045A1 (es)
CO (1) CO2021000043A2 (es)
CR (1) CR20210007A (es)
DK (1) DK3820873T3 (es)
EA (1) EA202092975A1 (es)
EC (1) ECSP21001770A (es)
ES (1) ES2933980T3 (es)
FI (2) FI3820873T3 (es)
HR (1) HRP20230009T1 (es)
HU (1) HUE060963T2 (es)
IL (3) IL289871B2 (es)
JO (1) JOP20210005B1 (es)
LT (1) LT3820873T (es)
MA (2) MA53126B1 (es)
MD (1) MD3820873T2 (es)
MX (2) MX2021000375A (es)
MY (1) MY198962A (es)
PE (1) PE20210400A1 (es)
PH (1) PH12021550049A1 (es)
PL (1) PL3820873T3 (es)
PT (1) PT3820873T (es)
RS (1) RS63809B1 (es)
SA (1) SA521421008B1 (es)
SG (1) SG11202100148TA (es)
SI (1) SI3820873T1 (es)
TW (1) TWI702219B (es)
UA (1) UA127507C2 (es)
WO (1) WO2020014435A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102710603B1 (ko) 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
MX2022000279A (es) 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
KR20220113695A (ko) 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
TW202146007A (zh) * 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4247363A1 (en) * 2020-11-23 2023-09-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
MX2023009374A (es) * 2021-02-16 2023-08-16 Genentech Inc Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib.
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
EP4472982A1 (en) * 2022-02-01 2024-12-11 Eli Lilly and Company Processes for the preparation of selective estrogen receptor degraders
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
KR20250105413A (ko) 2022-11-02 2025-07-08 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
EP4704841A1 (en) 2023-05-05 2026-03-11 Eli Lilly and Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer
EP4709386A1 (en) 2023-05-11 2026-03-18 Astrazeneca AB Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
ATE321754T1 (de) * 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7223738B2 (en) * 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
EP1497277A1 (en) * 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
EP1709021B1 (en) * 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
BR112015030595A2 (pt) * 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
KR102785474B1 (ko) * 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
US10125135B2 (en) * 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
SI3820873T1 (sl) 2023-02-28
NZ771718A (en) 2024-05-31
US11634426B2 (en) 2023-04-25
BR122023025061A2 (pt) 2024-02-20
CR20210007A (es) 2021-02-08
FI3820873T3 (fi) 2023-03-02
JOP20210005A1 (ar) 2021-01-10
CN112638916A (zh) 2021-04-09
ES2933980T3 (es) 2023-02-15
FIC20260010I1 (fi) 2026-04-07
MX2021000375A (es) 2021-05-27
IL289871B (en) 2022-10-01
JP2024169490A (ja) 2024-12-05
SA521421008B1 (ar) 2022-10-30
JP2023081954A (ja) 2023-06-13
KR102783756B1 (ko) 2025-03-21
AR134662A2 (es) 2026-03-04
MD3820873T2 (ro) 2023-05-31
TWI702219B (zh) 2020-08-21
JP6995241B2 (ja) 2022-01-14
EA202092975A1 (ru) 2021-04-14
US20230234960A1 (en) 2023-07-27
IL289871A (en) 2022-03-01
DK3820873T3 (da) 2022-12-12
PT3820873T (pt) 2022-12-23
JP2022037102A (ja) 2022-03-08
CO2021000043A2 (es) 2021-01-18
IL280065B (en) 2022-04-01
JP7241211B2 (ja) 2023-03-16
US11117902B2 (en) 2021-09-14
MA53124B1 (fr) 2023-02-28
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
EP4155310A1 (en) 2023-03-29
AR134487A2 (es) 2026-01-21
JP7746496B2 (ja) 2025-09-30
CA3105501C (en) 2023-10-31
CN117379428A (zh) 2024-01-12
KR102589886B1 (ko) 2023-10-17
JP2021530484A (ja) 2021-11-11
IL295598B1 (en) 2023-05-01
JP2025186400A (ja) 2025-12-23
AR115694A1 (es) 2021-02-17
IL295598A (en) 2022-10-01
UA127507C2 (uk) 2023-09-13
CL2021000045A1 (es) 2021-07-19
KR20230005404A (ko) 2023-01-09
MA53126B1 (fr) 2023-02-28
AU2019299947B2 (en) 2022-03-17
SG11202100148TA (en) 2021-02-25
AU2019299947A1 (en) 2021-01-07
JP7557564B2 (ja) 2024-09-27
HRP20230009T1 (hr) 2023-02-17
AU2022203969B2 (en) 2024-02-15
EP3820873B1 (en) 2022-11-23
MY198962A (en) 2023-10-05
AU2022203969A1 (en) 2022-06-30
US20210403480A1 (en) 2021-12-30
IL295598B2 (en) 2023-09-01
RS63809B1 (sr) 2023-01-31
JP7009672B1 (ja) 2022-01-25
KR20230148386A (ko) 2023-10-24
TW202019935A (zh) 2020-06-01
BR112020025654A2 (pt) 2021-04-06
US20200017516A1 (en) 2020-01-16
KR20210019065A (ko) 2021-02-19
IL280065A (en) 2021-03-01
LT3820873T (lt) 2023-01-10
IL289871B2 (en) 2023-02-01
CA3105501A1 (en) 2020-01-16
PE20210400A1 (es) 2021-03-02
CN112638916B (zh) 2023-09-12
PL3820873T3 (pl) 2023-02-13
MA53126A (fr) 2021-05-19
MA53124A (fr) 2021-05-19
JOP20210005B1 (ar) 2023-03-28
PH12021550049A1 (en) 2021-09-20
JP2022050591A (ja) 2022-03-30
KR102550538B1 (ko) 2023-07-04
WO2020014435A1 (en) 2020-01-16
EP3820873A1 (en) 2021-05-19
HUE060963T2 (hu) 2023-04-28
US20200347073A1 (en) 2020-11-05
US10654866B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
ECSP21001770A (es) Degradadores selectivos del receptor de estrógeno
ECSP21001786A (es) Degradadores selectivos del receptor de estrógeno
PL3824347T3 (pl) Urządzenie do wizualizacji tkanek
CL2018000947S1 (es) Automóvil
EP3954351C0 (en) ANKLE-ASSISTED EXOSKELETON DEVICE
EP3890340A4 (en) Input device
CL2018001940S1 (es) Automóvil
EP3971658C0 (en) WEARABLE DEVICE
EP3788441A4 (en) INTEGRATED DEVICES FOR SQUEEZE LIGHT GENERATION
CL2020000154A1 (es) Compuestos absorbentes
DE112020001082A5 (de) Löschvorrichtung
DK3930878T3 (da) Tværfiltreringsanordning
DK3746678T3 (da) Fastspændingsindretning
EP3702825A4 (en) HEAD MOUNTED DISPLAY DEVICE
DK3794946T3 (da) Elastisk støtteindretning
EP4063721A4 (en) LAMP DEVICE
CL2020000902A1 (es) Conexión flexible antisísmica
CL2018000791S1 (es) Automóvil
ECSP17014972A (es) Compuestos de azetidiniloxifenilpirrolidina
ECSP17050310A (es) Ciclopropabenzofuranil-piridopirazindionas novedosas
JOP20210232A1 (ar) جهاز شيشة
EP3803547C0 (en) INPUT DEVICE
KR102314030B9 (ko) 광학 장치
EP4082949A4 (en) Platen carry device
DE112018007558A5 (de) Führungsvorrichtung